XML 23 R11.htm IDEA: XBRL DOCUMENT v3.25.3
Marketable Securities
 9 Months Ended
Oct. 31, 2025
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The following is a summary of our marketable securities (in thousands): 
As of October 31, 2025
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Treasury bills and U.S. government securities(1)
$599,844 $321 $— $600,165 
Corporate bonds163,381 — (96)163,285 
Commercial paper(2)
9,792 8 — 9,800 
Yankee bonds2,889 — (4)2,885 
Total marketable securities$775,906 $329 $(100)$776,135 
(1) Additional treasury bills with both amortized cost and estimated fair value of $24.0 million are included in cash and cash equivalents due to their original maturities of three months or less.
(2) Additional commercial paper with both amortized cost and estimated fair value of $28.4 million is included in cash and cash equivalents due to its original maturity of three months or less.
As of January 31, 2025
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Treasury bills and U.S. government securities$703,740 $— $(421)$703,319 
Corporate bonds93,989 36 — 94,025 
Commercial paper42,371 20 — 42,391 
Yankee bonds4,707 — (7)4,700 
Total marketable securities$844,807 $56 $(428)$844,435 
As of October 31, 2025 and January 31, 2025, $121.6 million and $94.1 million, respectively, of our marketable securities had remaining contractual maturities of one year or more.
As of October 31, 2025 and January 31, 2025, $7.9 million and $2.4 million, respectively, of interest receivable was included in prepaid expenses and other current assets on the condensed consolidated balance sheets. We did not recognize an allowance for credit losses against interest receivable as of October 31, 2025 or January 31, 2025.
Unrealized losses during the periods presented are a result of changes in market conditions. We do not believe that any unrealized losses are attributable to credit-related factors based on our evaluation of available evidence. To determine whether a decline in value is related to credit loss, we evaluate, among other factors, the extent to which the fair value is less than the amortized cost basis and any adverse conditions specifically related to an issuer of a security or its industry.